Epstein-Barr Virus and COVID-19 Induced Systemic Inflammatory Response Syndrome and Guillain-Barré Syndrome - A Novel Case Report
Article Sidebar
Main Article Content
Abstract
gentleman without any comorbidities was admitted to the hospital with complaints of fever and sore throat. On examination and investigation, he was found to have jaundice and acute kidney injury with biochemical pancreatitis. He was being treated conservatively with IV Fluids and IV Antibiotics. Investigations revealed that he was suffering from the Epstein-Barr virus, and he improved with the ongoing treatment. But on day 5 of admission, he suddenly developed bilateral facial nerve palsy with weakness of the bilateral lower limbs. The nerve conduction velocity test was suggestive of Guillain-Barré syndrome. Incidentally, on the same day, he also tested positive for COVID-19. He was then initiated on IV Immunoglobulin and showed a remarkable response, with improvement in limb power and facial weakness. He was discharged after completing 5 days of IV immunoglobulin treatment for further outpatient care, including continuation of physiotherapy at home.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their articles and grant the journal the right of first publication under the Creative Commons Attribution (CC BY) license, which allows others to share and adapt the work with proper attribution.
References
Muley SA, Shefner JM, Rabinstein AA, Goddeau RP. Guillain Barre syndrome in adults: Treatment and prognosis. Up-ToDate. July 2022.
Sullivan JL, Hirsch MS, Kaplan SL, Bond S. Clinical manifestations and treatment of Epstein Barr virus infection. UpToDate. July 2022.
McIntosh K, Hirsch MS, Bogorodskaya M. COVID 19: Clinical features. UpToDate. July 2022.
Chakraborty RK, Burns B. Systemic inflammatory response syndrome. StatPearls. Treasure Island (FL): StatPearls Publish-ing; 2022 Jan. PMID: 31613449.
Spivack T, Chawla R, Marik PE. Epstein Barr virus associated hemophagocytic syndrome mimicking severe sepsis. J Emerg Trauma Shock. 2008;1(2):119 122. doi:10.4103/0974-2700.43198. PMID: 19561991.
Masi P, Hekimian G, Lejeune M, Chommeloaux J, Desnos C, Pineton De Chambrun M, Martin Toutain I, Nieszkowska A, Lebreton G, Brechot N, Schmidt M, Luyt CE, Combes A, Frere C. Systemic inflammatory response syndrome is a major con-tributor to COVID 19 associated coagulopathy. Circulation. 2020;142(6):611 614. doi:10.1161/CIRCULATIONAHA.120.048925. PMID: 32776849.
Nguyen TP, Taylor RS. Guillain Barre syndrome. StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 Jan. PMID: 30335287.
Kim SY, Choe KW, Park S, Yoon D, Ock CY, Hong SW, Heo JY. Mild form of Guillain Barre syndrome in a patient with pri-mary Epstein Barr virus infection. Korean J Intern Med. 2016;31(6):1191 1193. doi:10.3904/kjim.2015.033. PMID: 26837010.
Khan F, Sharma P, Pandey S, Sharma D, Vijayavarman V, Kumar N, Shukla S, Dandu H, Jain A, Garg RK, Malhotra HS. COVID 19 associated Guillain Barre syndrome: Post infectious alone or neuroinvasive too? J Med Virol. 2021;93(10):6045 6049. doi:10.1002/jmv.27159. PMID: 34170552.